Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q8WWT9: Variant p.Ala254Asp

Na(+)/dicarboxylate cotransporter 3
Gene: SLC13A3
Feedback?
Variant information Variant position: help 254 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Alanine (A) to Aspartate (D) at position 254 (A254D, p.Ala254Asp). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from small size and hydrophobic (A) to medium size and acidic (D) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In ARLIAK; unable to transport succinate, 2-oxoglutarate and N-acetylaspartate. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 254 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 602 The length of the canonical sequence.
Location on the sequence: help FLISIPYSASIGGTATLTGT A PNLILLGQLKSFFPQCDVVN The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         FLISIPYSASIGGTATLTGTAPNLILLGQLKSFFPQCDVVN

Mouse                         FLISIPYSASIGGTATLTGTAPNLILLGQLKSFFPQCDVVN

Rat                           FLISIPYSASIGGTATLTGTAPNLILLGQLKSFFPQCDVVN
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 602 Na(+)/dicarboxylate cotransporter 3
Topological domain 251 – 278 Extracellular
Alternative sequence 181 – 297 AAVRRNGLHTVPTEMQFLASTEAKDHPGETEVPLDLPADSRKEDEYRRNIWKGFLISIPYSASIGGTATLTGTAPNLILLGQLKSFFPQCDVVNFGSWFIFAFPLMLLFLLAGWLWI -> GIEPNTFLSEERLKLQAPLVIRLGQITESGQWNMSGNDVCNFRVLSFLPGGM. In isoform 2.
Alternative sequence 182 – 292 AVRRNGLHTVPTEMQFLASTEAKDHPGETEVPLDLPADSRKEDEYRRNIWKGFLISIPYSASIGGTATLTGTAPNLILLGQLKSFFPQCDVVNFGSWFIFAFPLMLLFLLA -> KTTLGRQRFHWICRLTPGRRMNIVGTSGRASSSPSPTQPVLGAQPHSRAQPLTSSCLASSR. In isoform 4 and isoform 5.



Literature citations
SLC13A3 variants cause acute reversible leukoencephalopathy and alpha-ketoglutarate accumulation.
Dewulf J.P.; Wiame E.; Dorboz I.; Elmaleh-Berges M.; Imbard A.; Dumitriu D.; Rak M.; Bourillon A.; Helaers R.; Malla A.; Renaldo F.; Boespflug-Tanguy O.; Vincent M.F.; Benoist J.F.; Wevers R.A.; Schlessinger A.; Van Schaftingen E.; Nassogne M.C.; Schiff M.;
Ann. Neurol. 85:385-395(2019)
Cited for: FUNCTION; INVOLVEMENT IN ARLIAK; VARIANTS ARLIAK ASP-254 AND SER-548; CHARACTERIZATION OF VARIANTS ARLIAK ASP-254 AND SER-548; BIOPHYSICOCHEMICAL PROPERTIES; TRANSPORTER ACTIVITY;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.